Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to start Phase III testing next year of

Read the full 426 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE